Stockscreener 앱 받기
2.63
3.54%
0.09
시간 외 거래:
2.58
-0.05
-1.90%
Aixcrypto Holdings Inc 주식(AIXC)의 최신 뉴스
An analyst sees good growth prospects for AIxCrypto Holdings Inc (AIXC) - Setenews
AIxCrypto Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its 'Three Driving Forces' Strategy to Become the No. 1 Gateway to AI Web3 and Bridge Between Web2 and Web3 - Reuters
What's Going On With Faraday Future Stock Monday? - Sahm
Faraday Future (NASDAQ: FFAI) FX Super One Parts Reach Long Beach, Enter Pilot Build - Stock Titan
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Completes its “Dual Flywheel, Dual Bridge, and Dual Listed-Company” Structure; First batch of FX Super One Complete Sets of Components to Arrive at Port of Long Beach Next Week - GlobeNewswire Inc.
AIxCrypto Holdings Regains Nasdaq Compliance After Issue - The Globe and Mail
AIxCrypto Holdings Rebrands, Unveils New Strategy - The Globe and Mail
AIxCrypto Holdings, Inc. Rebrands and Launches New Strategy - TradingView
AIxCrypto Rebrands as AIxCrypto Holdings, Inc., Unveils Bold Web3 Strategy - Bitget
QUALIGEN THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - MarketScreener
Faraday Future Advances Dual-Listed Framework with AIxCrypto Holdings Inc. Name Change and Strategic Initiatives - Quiver Quantitative
Faraday Future Completes Formation of "FFAI+AIXC" Dual-Flywheel, Dual-Bridge, and Dual-Listed Company System; Its Majority Owned Crypto Company Renamed as AIxCrypto (Nasdaq: AIXC) - Nasdaq
Aixcrypto Holdings Inc appoints Jie Sheng as chairman of boardSEC filing - MarketScreener
AIxCrypto rebrands from Qualigen, unveils three-part strategy By Investing.com - Investing.com Nigeria
AIxCrypto rebrands, begins trading under ‘AIXC’ ticker - TipRanks
Qualigen Therapeutics Rebrands to AIxCrypto Holdings - MSN
AIxCrypto Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its "Three Driving Forces" Strategy to Become the No.1 Gateway to AI Web3 and a Bridge Between Web2 and Web3 - The AI Journal
Jia Yueting-backed listed company QLGN has been renamed AIxCrypto and will launch stock tokenization business - Bitget
Qualigen Therapeutics, Inc. will Change its Name to AIxCrypto Holdings, Inc - MarketScreener
"Biotech-to-DeAI Transformation: AIxCrypto Rises as the Portal to the Web3 Age" - Bitget
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: On November 20, QLGN, which is Strategically Invested in and Controlled by FFAI, will Begin Using its New Name, AIxCrypto, and will be Traded Under AIXC - The Manila Times
Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy - Investing News Network
Faraday Future Becomes Majority Shareholder in Qualigen Therapeutics, Preparing for Corporate Rebranding and Strategic Transformation on November 20 - Quiver Quantitative
Qualigen (NASDAQ: QLGN) to Rebrand as AIxCrypto, Launch AI × Web3 Strategy Nov. 20 - Stock Titan
QLGN to Become AIxCrypto as Faraday Future (NASDAQ: FFAI) Takes Control, AIXC Ticker - Stock Titan
Qualigen Therapeutics Inc. Announces Rebranding to AIxCrypto and Launch of Web3 Initiatives - Quiver Quantitative
Qualigen Therapeutics to Rebrand as AIxCrypto After - GlobeNewswire
Qualigen (NASDAQ: QLGN) chooses BitGo for $30M C10 treasury in top 10 crypto basket - Stock Titan
$16B Liquidated in Crypto Sell-Off — Qualigen Launches C10 Treasury Buying Program Next Week - Stock Titan
Co-CEO Jerry Wang & CFO Koti Meka join Qualigen; Board adds 3 directors and auditor switches to MGO for FY2025 - Stock Titan
$41M Crypto Transformation: Qualigen Partners with EV Giant Faraday Future for Web3 Evolution to CXC10 - Stock Titan
$41M Strategic Investment: EV Maker Faraday Future Pivots to Crypto with Majority Stake in Qualigen - Stock Titan
Qualigen Secures Nasdaq Listing Status with $4.5M Strategic Funding, Addresses All Compliance Issues - Stock Titan
Qualigen's Cancer Treatment Patent Portfolio Expands to 25 Countries, Protection Until 2040 - Stock Titan
Qualigen Therapeutics, Inc. Appoints Robert B. Lim to Serve as Chair of the Audit Committee of the Board - MarketScreener
Nasdaq Threatens to Delist Qualigen on May 5: Company Plans Last-Minute Appeal - Stock Titan
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - MarketScreener
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - MarketScreener
Qualigen Therapeutics, Inc. Appoints Graydon Bensler as an Independent Member - MarketScreener
Qualigen Therapeutics : Shares Expected to Begin Trading on Split Adjusted Basis on November 5, 2024 Form 8 K - MarketScreener
Qualigen Therapeutics, Inc. Announces Chief Executive Officer Changes - MarketScreener
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - MarketScreener
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. - MarketScreener
Qualigen Therapeutics to Seek Acquisitions - MarketScreener
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering - MarketScreener
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - MarketScreener
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 - MarketScreener
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors - MarketScreener
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors - MarketScreener
Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023 - MarketScreener
QUALIGEN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - MarketScreener
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders - MarketScreener
Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302 - MarketScreener
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications - MarketScreener
Qualigen Therapeutics, Inc. Announces Executive Changes - MarketScreener
Qualigen Therapeutics' QN-302 Receives FDA's Orphan Drug Designation - MarketScreener
Qualigen Therapeutics, Inc. Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors - MarketScreener
Qualigen Therapeutics, Inc. Announces Formation and First Meeting of QN-302 Scientific Advisory Board - MarketScreener
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials - MarketScreener
Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302 - MarketScreener
Qualigen Therapeutics : Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results - MarketScreener
Qualigen Therapeutics, Inc. Elects Tariq Arshad as Its Senior Vice President and Chief Medical Officer - MarketScreener
Qualigen Therapeutics, Inc. Announces Management Changes - MarketScreener
Qualigen Therapeutics : Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack Diagnostics Products in China - MarketScreener
QUALIGEN THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K) - MarketScreener
Qualigen Therapeutics, Inc. Announces Appointment of Amy Broidrick as Executive Vice President and Chief Strategy Officer - MarketScreener
Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China - Stock Titan
Qualigen Therapeutics, Inc. Appoints Amy Broidrick to Board of Directors - MarketScreener
1.77%
0.49%
자본화:
|
볼륨(24시간):